Pharmacokinetics

A graph depicting a typical time course of drug plasma concentration over 96 hours, with oral administrations every 24 hours. The main pharmacokinetic metrics are annotated. Steady state is reached after about 5 × 12 = 60 hours.

Pharmacokinetics (from Ancient Greek pharmakon "drug" and kinetikos "moving, putting in motion"; see chemical kinetics), sometimes abbreviated as PK, is a branch of pharmacology dedicated to describing how the body affects a specific substance after administration. ^[1] The substances of interest include any chemical xenobiotic such as pharmaceutical drugs, pesticides, food additives, cosmetics, etc. It attempts to analyze chemical metabolism and to discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body. Pharmacokinetics is based on mathematical modeling that places great emphasis on the relationship between drug plasma concentration and the time elapsed since the drug's administration. Pharmacokinetics is the study of how an organism affects the drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism. Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models.

IUPAC definition

Pharmacokinetics:

1. Process of the uptake of drugs by the body, the biotransformation they undergo, the distribution of the drugs and their metabolites in the tissues, and the elimination of the drugs and their metabolites from the body over a period of time.
2. Study of more such related processes ^[2]

ADME

Main article: ADME

A number of phases occur once the drug enters into contact with the organism, these are described using the acronym ADME (or LADME if liberation is included as a separate step from absorption):

• Liberation – the process of the active ingredient separating from its pharmaceutical formulation. ^{[3] [4]} See also IVIVC.
• Absorption – the process of a drug entering into systemic circulation from the site of administration
• Distribution – the dispersion or dissemination of substances throughout the fluids and tissues of the body.
• Metabolism (or biotransformation, or inactivation) – the chemical reactions of the drug and irreversible breakdown into metabolites (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes)
• Excretion – the removal of the substance or metabolites from the body. In rare cases, some drugs irreversibly accumulate in body tissue. ^{[ citation needed ]}

Some textbooks combine the first two phases as the drug is often administered in an active form, which means that there is no liberation phase. Others include a phase that combines distribution, metabolism and excretion into a disposition phase. Other authors include the drug's toxicological aspect in what is known as ADME-Tox or ADMET. The two phases of metabolism and excretion can be grouped together under the title elimination.

The study of these distinct phases involves the use and manipulation of basic concepts in order to understand the process dynamics. For this reason, in order to fully comprehend the kinetics of a drug it is necessary to have detailed knowledge of a number of factors such as: the properties of the substances that act as excipients, the characteristics of the appropriate biological membranes and the way that substances can cross them, or the characteristics of the enzyme reactions that inactivate the drug.

Metrics

The following are the most commonly measured pharmacokinetic metrics: ^[5] The units of the dose in the table are expressed in moles (mol) and molar (M). To express the metrics of the table in units of mass, instead of Amount of substance, simply replace 'mol' with 'g' and 'M' with 'g/L'. Similarly, other units in the table may be expressed in units of an equivalent dimension by scaling. ^[6]

Pharmacokinetic metrics

Characteristic	Description	Symbol	Unit	Formula	Worked example value
Dose	Amount of drug administered.	${\displaystyle D}$	${\displaystyle \mathrm {mol} }$	Design parameter	500 mmol
Dosing interval	Time interval between drug dose administrations.	${\displaystyle \tau }$	${\displaystyle \mathrm {h} }$	Design parameter	24 h
Maximum serum concentration	The peak plasma concentration of a drug after administration.	${\displaystyle C_{\text{max}}}$	${\displaystyle \mathrm {mmol/L} }$	Direct measurement	60.9 mmol/L
Minimum time for Cmax	Minimum time taken to reach Cmax.	${\displaystyle t_{\text{max}}}$	${\displaystyle \mathrm {h} }$	Direct measurement	3.9 h
Minimum plasma concentration	The lowest (trough) concentration that a drug reaches before the next dose is administered.	${\displaystyle C_{{\text{min}},{\text{ss}}}}$	${\displaystyle \mathrm {mmol/L} }$	${\displaystyle C_{min}={\frac {SFDk_{a}}{V_{d}(k_{a}-k)}}\times \{{\frac {e^{-k_{e}\tau }}{1-e^{-k_{e}\tau }}}-{\frac {e^{-k_{a}\tau }}{1-e^{-k_{a}\tau }}}\}}$	27.7 mmol/L
Average plasma concentration	The average plasma concentration of a drug over the dosing interval in steady state.	${\displaystyle C_{{\text{av}},{\text{ss}}}}$	${\displaystyle \mathrm {h\times mmol/L} }$	${\displaystyle {\frac {AUC_{\tau ,{\text{ss}}}}{\tau }}}$	55.0 h×mmol/L
Volume of distribution	The apparent volume in which a drug is distributed (i.e., the parameter relating drug concentration in plasma to drug amount in the body).	${\displaystyle V_{\text{d}}}$	${\displaystyle \mathrm {L} }$	${\displaystyle {\frac {D}{C_{0}}}}$	6.0 L
Concentration	Amount of drug in a given volume of plasma.	${\displaystyle C_{0},C_{\text{ss}}}$	${\displaystyle \mathrm {mmol/L} }$	${\displaystyle {\frac {D}{V_{\text{d}}}}}$	83.3 mmol/L
Absorption half-life	The time required for 50% of a given dose of drug to be absorbed into the systemic circulation. [7]	${\displaystyle t_{{\frac {1}{2}}a}}$	${\displaystyle \mathrm {h} }$	${\displaystyle {\frac {\ln(2)}{k_{\text{a}}}}}$	1.0 h
Absorption rate constant	The rate at which a drug enters into the body for oral and other extravascular routes.	${\displaystyle k_{\text{a}}}$	${\displaystyle \mathrm {h} ^{-1}}$	${\displaystyle {\frac {\ln(2)}{t_{{\frac {1}{2}}a}}}}$	0.693 h−1
Elimination half-‍life	The time required for the concentration of the drug to reach half of its original value.	${\displaystyle t_{{\frac {1}{2}}b}}$	${\displaystyle \mathrm {h} }$	${\displaystyle {\frac {\ln(2)}{k_{\text{e}}}}}$	12 h
Elimination rate constant	The rate at which a drug is removed from the body.	${\displaystyle k_{\text{e}}}$	${\displaystyle \mathrm {h} ^{-1}}$	${\displaystyle {\frac {\ln(2)}{t_{{\frac {1}{2}}b}}}={\frac {CL}{V_{\text{d}}}}}$	0.0578 h−1
Infusion rate	Rate of infusion required to balance elimination.	${\displaystyle k_{\text{in}}}$	${\displaystyle \mathrm {mol/h} }$	${\displaystyle C_{\text{ss}}\cdot CL}$	50 mmol/h
Area under the curve	The integral of the concentration-time curve (after a single dose or in steady state).	${\displaystyle AUC_{0-\infty }}$	${\displaystyle \mathrm {M} \cdot \mathrm {s} }$	${\displaystyle \int _{0}^{\infty }C\,\mathrm {d} t}$	1,320 h×mmol/L
		${\displaystyle AUC_{\tau ,{\text{ss}}}}$	${\displaystyle \mathrm {M} \cdot \mathrm {s} }$	${\displaystyle \int _{t}^{t+\tau }C\,\mathrm {d} t}$
Clearance	The volume of plasma cleared of the drug per unit time.	${\displaystyle CL}$	${\displaystyle \mathrm {m} ^{3}/\mathrm {s} }$	${\displaystyle V_{\text{d}}\cdot k_{\text{e}}={\frac {D}{AUC}}}$	0.38 L/h
Bioavailability	The systemically available fraction of a drug.	${\displaystyle f}$	Unitless	${\displaystyle {\frac {AUC_{\text{po}}\cdot D_{\text{iv}}}{AUC_{\text{iv}}\cdot D_{\text{po}}}}}$	0.8
Fluctuation	Peak–trough fluctuation within one dosing interval at steady state.	${\displaystyle \%PTF}$	${\displaystyle \%}$	${\displaystyle 100{\frac {C_{{\text{max}},{\text{ss}}}-C_{{\text{min}},{\text{ss}}}}{C_{{\text{av}},{\text{ss}}}}}}$ where ${\displaystyle C_{{\text{av}},{\text{ss}}}={\frac {AUC_{\tau ,{\text{ss}}}}{\tau }}}$	41.8%

In pharmacokinetics, steady state refers to the situation where the overall intake of a drug is fairly in dynamic equilibrium with its elimination. In practice, it is generally considered that once regular dosing of a drug is started, steady state is reached after 3 to 5 times its half-life. In steady state and in linear pharmacokinetics, AUC_τ=AUC_∞. ^[8]

Modeling

Models have been developed to simplify conceptualization of the many processes that take place in the interaction between an organism and a chemical substance. Pharmacokinetic modelling may be performed either by noncompartmental or compartmental methods. Multi-compartment models provide the best approximations to reality; however, the complexity involved in adding parameters with that modelling approach means that monocompartmental models and above all two compartmental models are the most-frequently used. The model outputs for a drug can be used in industry (for example, in calculating bioequivalence when designing generic drugs) or in the clinical application of pharmacokinetic concepts. Clinical pharmacokinetics provides many performance guidelines for effective and efficient use of drugs for human-health professionals and in veterinary medicine.

Models generally take the form of mathematical formulas that have a corresponding graphical representation. The use of these models allows an understanding of the characteristics of a molecule, as well as how a particular drug will behave given information regarding some of its basic characteristics such as its acid dissociation constant (pKa), bioavailability and solubility, absorption capacity and distribution in the organism. A variety of analysis techniques may be used to develop models, such as nonlinear regression or curve stripping.

Noncompartmental analysis

Noncompartmental methods estimate PK parameters directly from a table of concentration-time measurements. Noncompartmental methods are versatile in that they do not assume any specific model and generally produce accurate results acceptable for bioequivalence studies. Total drug exposure is most often estimated by area under the curve (AUC) methods, with the trapezoidal rule (numerical integration) the most common method. Due to the dependence on the length of x in the trapezoidal rule, the area estimation is highly dependent on the blood/plasma sampling schedule. That is, the closer time points are, the closer the trapezoids reflect the actual shape of the concentration-time curve. The number of time points available in order to perform a successful NCA analysis should be enough to cover the absorption, distribution and elimination phase to accurately characterize the drug. Beyond AUC exposure measures, parameters such as Cmax (maximum concentration), Tmax (time to maximum concentration), CL and Vd can also be reported using NCA methods.

Compartmental analysis

Compartment models methods estimate the concentration-time graph by modeling it as a system of differential equations. These models are based on a consideration of an organism as a number of related compartments. Both single compartment and multi-compartment models are in use. PK compartmental models are often similar to kinetic models used in other scientific disciplines such as chemical kinetics and thermodynamics. The advantage of compartmental over noncompartmental analysis is the ability to modify parameters and to extrapolate to novel situations. The disadvantage is the difficulty in developing and validating the proper model. Although compartment models have the potential to realistically model the situation within an organism, models inevitably make simplifying assumptions and will not be applicable in all situations. However complicated and precise a model may be, it still does not truly represent reality despite the effort involved in obtaining various distribution values for a drug. This is because the concept of distribution volume is a relative concept that is not a true reflection of reality. The choice of model therefore comes down to deciding which one offers the lowest margin of error for the drug involved.

Single-compartment model

Graph representing the monocompartmental action model

The simplest PK compartmental model is the one-compartmental PK model. This models an organism as one homogenous compartment. This monocompartmental model presupposes that blood plasma concentrations of the drug are the only information needed to determine the drug's concentration in other fluids and tissues. For example, the concentration in other areas may be approximately related by known, constant factors to the blood plasma concentration.

In this one-compartment model, the most common model of elimination is first order kinetics, where the elimination of the drug is directly proportional to the drug's concentration in the organism. This is often called linear pharmacokinetics, as the change in concentration over time can be expressed as a linear differential equation ${\textstyle {\frac {dC}{dt}}=-k_{\text{el}}C}$. Assuming a single IV bolus dose resulting in a concentration ${\displaystyle C_{\text{initial}}}$ at time ${\displaystyle t=0}$, the equation can be solved to give ${\displaystyle C=C_{\text{initial}}\times e^{-k_{\text{el}}\times t}}$.

Two-compartment model

Not all body tissues have the same blood supply, so the distribution of the drug will be slower in these tissues than in others with a better blood supply. In addition, there are some tissues (such as the brain tissue) that present a real barrier to the distribution of drugs, that can be breached with greater or lesser ease depending on the drug's characteristics. If these relative conditions for the different tissue types are considered along with the rate of elimination, the organism can be considered to be acting like two compartments: one that we can call the central compartment that has a more rapid distribution, comprising organs and systems with a well-developed blood supply; and a peripheral compartment made up of organs with a lower blood flow. Other tissues, such as the brain, can occupy a variable position depending on a drug's ability to cross the barrier that separates the organ from the blood supply.

Two-compartment models vary depending on which compartment elimination occurs in. The most common situation is that elimination occurs in the central compartment as the liver and kidneys are organs with a good blood supply. However, in some situations it may be that elimination occurs in the peripheral compartment or even in both. This can mean that there are three possible variations in the two compartment model, which still do not cover all possibilities. ^[9]

Multi-compartment models

Further information: Multi-compartment model

Graphs for absorption and elimination for a non-linear pharmacokinetic model

In the real world, each tissue will have its own distribution characteristics and none of them will be strictly linear. The two-compartment model may not be applicable in situations where some of the enzymes responsible for metabolizing the drug become saturated, or where an active elimination mechanism is present that is independent of the drug's plasma concentration. If we label the drug's volume of distribution within the organism Vd_F and its volume of distribution in a tissue Vd_T the former will be described by an equation that takes into account all the tissues that act in different ways, that is:

${\displaystyle Vd_{F}=Vd_{T1}+Vd_{T2}+Vd_{T3}+\cdots +Vd_{Tn}\,}$

This represents the multi-compartment model with a number of curves that express complicated equations in order to obtain an overall curve. A number of computer programs have been developed to plot these equations. ^[9] The most complex PK models (called PBPK models) rely on the use of physiological information to ease development and validation.

The graph for the non-linear relationship between the various factors is represented by a curve; the relationships between the factors can then be found by calculating the dimensions of different areas under the curve. The models used in non-linear pharmacokinetics are largely based on Michaelis–Menten kinetics. A reaction's factors of non-linearity include the following:

• Multiphasic absorption: Drugs injected intravenously are removed from the plasma through two primary mechanisms: (1) Distribution to body tissues and (2) metabolism + excretion of the drugs. The resulting decrease of the drug's plasma concentration follows a biphasic pattern (see figure).

  

  Plasma drug concentration vs time after an IV dose

  • Alpha phase: An initial phase of rapid decrease in plasma concentration. The decrease is primarily attributed to drug distribution from the central compartment (circulation) into the peripheral compartments (body tissues). This phase ends when a pseudo-equilibrium of drug concentration is established between the central and peripheral compartments.
  • Beta phase: A phase of gradual decrease in plasma concentration after the alpha phase. The decrease is primarily attributed to drug elimination, that is, metabolism and excretion. ^[10]
  • Additional phases (gamma, delta, etc.) are sometimes seen. ^[11]
• A drug's characteristics make a clear distinction between tissues with high and low blood flow.
• Enzymatic saturation: When the dose of a drug whose elimination depends on biotransformation is increased above a certain threshold the enzymes responsible for its metabolism become saturated. The drug's plasma concentration will then increase disproportionately and its elimination will no longer be constant.
• Induction or enzymatic inhibition: Some drugs have the capacity to inhibit or stimulate their own metabolism, in negative or positive feedback reactions. As occurs with fluvoxamine, fluoxetine and phenytoin. As larger doses of these pharmaceuticals are administered the plasma concentrations of the unmetabolized drug increases and the elimination half-life increases. It is therefore necessary to adjust the dose or other treatment parameters when a high dosage is required.
• The kidneys can also establish active elimination mechanisms for some drugs, independent of plasma concentrations.

It can therefore be seen that non-linearity can occur because of reasons that affect the entire pharmacokinetic sequence: absorption, distribution, metabolism and elimination.

Bioavailability

Different forms of tablets, which will have different pharmacokinetic behaviours after their administration.

Main article: Bioavailability

At a practical level, a drug's bioavailability can be defined as the proportion of the drug that reaches its site of action. From this perspective the intravenous administration of a drug provides the greatest possible bioavailability, and this method is considered to yield a bioavailability of 1 (or 100%). Bioavailability of other delivery methods is compared with that of intravenous injection (absolute bioavailability) or to a standard value related to other delivery methods in a particular study (relative bioavailability).

${\displaystyle B_{A}={\frac {[ABC]_{P}\cdot D_{IV}}{[ABC]_{IV}\cdot D_{P}}}}$

${\displaystyle {\mathit {B}}_{R}={\frac {[ABC]_{A}\cdot {\text{dose}}_{B}}{[ABC]_{B}\cdot {\text{dose}}_{A}}}}$

Once a drug's bioavailability has been established it is possible to calculate the changes that need to be made to its dosage in order to reach the required blood plasma levels. Bioavailability is, therefore, a mathematical factor for each individual drug that influences the administered dose. It is possible to calculate the amount of a drug in the blood plasma that has a real potential to bring about its effect using the formula:

${\displaystyle De=B\cdot Da\,}$

where De is the effective dose, B bioavailability and Da the administered dose.

Therefore, if a drug has a bioavailability of 0.8 (or 80%) and it is administered in a dose of 100 mg, the equation will demonstrate the following:

De = 0.8 × 100 mg = 80 mg

That is the 100 mg administered represents a blood plasma concentration of 80 mg that has the capacity to have a pharmaceutical effect.

This concept depends on a series of factors inherent to each drug, such as: ^[12]

• Pharmaceutical form
• Chemical form
• Route of administration
• Stability
• Metabolism

These concepts, which are discussed in detail in their respective titled articles, can be mathematically quantified and integrated to obtain an overall mathematical equation:

${\displaystyle De=Q\cdot Da\cdot B\,}$

where Q is the drug's purity. ^[12]

${\displaystyle Va={\frac {Da\cdot B\cdot Q}{\tau }}}$

where ${\displaystyle Va}$ is the drug's rate of administration and ${\displaystyle \tau }$ is the rate at which the absorbed drug reaches the circulatory system.

Finally, using the Henderson-Hasselbalch equation, and knowing the drug's ${\displaystyle pKa\,}$ (pH at which there is an equilibrium between its ionized and non-ionized molecules), it is possible to calculate the non-ionized concentration of the drug and therefore the concentration that will be subject to absorption:

${\displaystyle \mathrm {pH} =\mathrm {pKa} +\log {\frac {B}{A}}}$

When two drugs have the same bioavailability, they are said to be biological equivalents or bioequivalents. This concept of bioequivalence is important because it is currently used as a yardstick in the authorization of generic drugs in many countries.

Analysis

Bioanalytical methods

Bioanalytical methods are necessary to construct a concentration-time profile. Chemical techniques are employed to measure the concentration of drugs in biological matrix, most often plasma. Proper bioanalytical methods should be selective and sensitive. For example, microscale thermophoresis can be used to quantify how the biological matrix/liquid affects the affinity of a drug to its target. ^{[13] [14]}

Mass spectrometry

Pharmacokinetics is often studied using mass spectrometry because of the complex nature of the matrix (often plasma or urine) and the need for high sensitivity to observe concentrations after a low dose and a long time period. The most common instrumentation used in this application is LC-MS with a triple quadrupole mass spectrometer. Tandem mass spectrometry is usually employed for added specificity. Standard curves and internal standards are used for quantitation of usually a single pharmaceutical in the samples. The samples represent different time points as a pharmaceutical is administered and then metabolized or cleared from the body. Blank samples taken before administration are important in determining background and ensuring data integrity with such complex sample matrices. Much attention is paid to the linearity of the standard curve; however it is common to use curve fitting with more complex functions such as quadratics since the response of most mass spectrometers is not linear across large concentration ranges. ^{[15] [16] [17]}

There is currently considerable interest in the use of very high sensitivity mass spectrometry for microdosing studies, which are seen as a promising alternative to animal experimentation. ^[18] Recent studies show that Secondary electrospray ionization (SESI-MS) can be used in drug monitoring, presenting the advantage of avoiding animal sacrifice. ^[19]

Population pharmacokinetics

Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest. ^{[20] [21] [22]} Certain patient demographic, pathophysiological, and therapeutical features, such as body weight, excretory and metabolic functions, and the presence of other therapies, can regularly alter dose-concentration relationships and can explain variability in exposures. For example, steady-state concentrations of drugs eliminated mostly by the kidney are usually greater in patients with kidney failure than they are in patients with normal kidney function receiving the same drug dosage. Population pharmacokinetics seeks to identify the measurable pathophysiologic factors and explain sources of variability that cause changes in the dose-concentration relationship and the extent of these changes so that, if such changes are associated with clinically relevant and significant shifts in exposures that impact the therapeutic index, dosage can be appropriately modified. An advantage of population pharmacokinetic modelling is its ability to analyse sparse data sets (sometimes only one concentration measurement per patient is available).

Clinical pharmacokinetics

Drugs where pharmacokinetic monitoring is recommended

Antiepileptic medication	Cardioactive medication	Immunosuppressor medication	Antibiotic medication
Phenytoin Carbamazepine Valproic acid Lamotrigine Ethosuximide Phenobarbital Primidone	Digoxin Lidocaine	Ciclosporin Tacrolimus Sirolimus Everolimus Mycophenolate	Gentamicin Tobramycin Amikacin Vancomycin
Bronchodilator medication	Cytostatic medication	Antiviral (HIV) medication	Coagulation factors
Theophylline	Methotrexate 5-Fluorouracil Irinotecan	+ Efavirenz Tenofovir Ritonavir	Factor VIII, Factor IX, Factor VIIa, Factor XI

Clinical pharmacokinetics (arising from the clinical use of population pharmacokinetics) is the direct application to a therapeutic situation of knowledge regarding a drug's pharmacokinetics and the characteristics of a population that a patient belongs to (or can be ascribed to).

An example is the relaunch of the use of ciclosporin as an immunosuppressor to facilitate organ transplant. The drug's therapeutic properties were initially demonstrated, but it was almost never used after it was found to cause nephrotoxicity in a number of patients. ^[23] However, it was then realized that it was possible to individualize a patient's dose of ciclosporin by analysing the patients plasmatic concentrations (pharmacokinetic monitoring). This practice has allowed this drug to be used again and has facilitated a great number of organ transplants.

Clinical monitoring is usually carried out by determination of plasma concentrations as this data is usually the easiest to obtain and the most reliable. The main reasons for determining a drug's plasma concentration include: ^[24]

• Narrow therapeutic range (difference between toxic and therapeutic concentrations)
• High toxicity
• High risk to life.

Ecotoxicology

Ecotoxicology is the branch of science that deals with the nature, effects, and interactions of substances that are harmful to the environment such as microplastics and other biosphere harmful substances. ^{[25] [26]} Ecotoxicology is studied in pharmacokinetics due to the substances responsible for harming the environment such as pesticides can get into the bodies of living organisms. The health effects of these chemicals is thus subject to research and safety trials by government or international agencies such as the EPA or WHO. ^{[27] [28]} How long these chemicals stay in the body, the lethal dose and other factors are the main focus of Ecotoxicology.

See also

• Bateman equation
• Blood alcohol concentration
• Biological half-life
• Bioavailability
• Cooperstown cocktail
• Enzyme kinetics
• Pharmacodynamics
• Idiosyncratic drug reaction
• Drug interaction
• Patlak plot
• Pharmacometrics
• Pharmacy
• Bioequivalence
• Generic drugs
• Physiologically based pharmacokinetic modelling
• Plateau principle
• Toxicokinetics

References

1. Pharmacokinetics. (2006). In Mosby's Dictionary of Medicine, Nursing & Health Professions . Philadelphia, PA: Elsevier Health Sciences. Retrieved December 11, 2008, from http://www.credoreference.com/entry/6686418 Archived 2016-04-11 at the Wayback Machine
2. Nordberg M, Duffus J, Templeton DM (1 January 2004). "Glossary of terms used in toxicokinetics (IUPAC Recommendations 2003)". Pure and Applied Chemistry. 76 (5): 1033–1082. doi: 10.1351/pac200476051033 . S2CID   98275795.
3. Koch HP, Ritschel WA (1986). "Liberation". Synopsis der Biopharmazie und Pharmakokinetik (in German). Landsberg, München: Ecomed. pp. 99–131. ISBN   3-609-64970-4.
4. Ruiz-Garcia A, Bermejo M, Moss A, Casabo VG (February 2008). "Pharmacokinetics in drug discovery". Journal of Pharmaceutical Sciences. 97 (2): 654–90. doi:10.1002/jps.21009. PMID   17630642.
5. AGAH working group PHARMACOKINETICS (2004-02-16). "Collection of terms, symbols, equations, and explanations of common pharmacokinetic and pharmacodynamic parameters and some statistical functions" (PDF). Arbeitsgemeinschaft für Angewandte Humanpharmakologie (AGAH) (Association for Applied Human Pharmacology). Archived from the original (PDF) on 2016-05-08. Retrieved 2011-04-04.
6. Hallare, Jericho; Gerriets, Valerie (2021), "Half Life", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   32119385, archived from the original on 2023-03-24, retrieved 2021-12-25
7. Hallare, Jericho; Gerriets, Valerie (2023), "Half Life", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   32119385, archived from the original on 2023-03-24, retrieved 2023-05-23
8. "Pharmacokinetics – Online content for student". Archived from the original on 2024-09-23. Retrieved 2024-02-02.
9. Milo Gibaldi, Donald Perrier. FarmacocinéticaReverté 1982 pages 1–10. ISBN   84-291-5535-X, 9788429155358
10. Gill SC, Moon-Mcdermott L, Hunt TL, Deresinski S, Blaschke T, Sandhaus RA (Sep 1999). "Phase I Pharmacokinetics of Liposomal Amikacin (MiKasome) in Human Subjects: Dose Dependence and Urinary Clearance". Abstr Intersci Conf Antimicrob Agents Chemother. 39: 33 (abstract no. 1195). Archived from the original on 2011-11-23. Retrieved 2011-08-25.
11. Weiner D, Gabrielsson J (2000). "PK24 – Non-linear kinetics – flow II". Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. Apotekarsocieteten. pp. 527–36. ISBN   91-86274-92-9. Archived from the original on 2023-01-25. Retrieved 2020-10-28.
12. Michael E. Winter, Mary Anne Koda-Kimple, Lloyd Y. Young, Emilio Pol Yanguas Farmacocinética clínica básica Ediciones Díaz de Santos, 1994 pgs. 8–14 ISBN   84-7978-147-5, 9788479781477 (in Spanish)
13. Baaske P, Wienken CJ, Reineck P, Duhr S, Braun D (March 2010). "Optical thermophoresis for quantifying the buffer dependence of aptamer binding". Angewandte Chemie. 49 (12): 2238–41. doi:10.1002/anie.200903998. PMID   20186894.
    • "A hot road to new drugs". Phys.org. February 24, 2010. Archived from the original on March 7, 2016. Retrieved February 10, 2011.
14. Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S (October 2010). "Protein-binding assays in biological liquids using microscale thermophoresis". Nature Communications. 1 (7): 100. Bibcode:2010NatCo...1..100W. doi: 10.1038/ncomms1093 . PMID   20981028.
15. Hsieh Y, Korfmacher WA (June 2006). "Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening". Current Drug Metabolism. 7 (5): 479–89. doi:10.2174/138920006777697963. PMID   16787157. S2CID   13612670.
16. Covey TR, Lee ED, Henion JD (October 1986). "High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples". Analytical Chemistry. 58 (12): 2453–60. doi:10.1021/ac00125a022. PMID   3789400.
17. Covey TR, Crowther JB, Dewey EA, Henion JD (February 1985). "Thermospray liquid chromatography/mass spectrometry determination of drugs and their metabolites in biological fluids". Analytical Chemistry. 57 (2): 474–81. doi:10.1021/ac50001a036. PMID   3977076.
18. Committee for Medicinal Products for Human Use (CHMP) (December 2009). "ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals" (PDF). European Medicines Agency, Evaluation of Medicines for Human Use. EMA/CPMP/ICH/286/1995. Archived from the original (PDF) on 15 June 2018. Retrieved 4 May 2013.
19. Li, Xue; Martinez-Lozano Sinues, Pablo; Dallmann, Robert; Bregy, Lukas; Hollmén, Maija; Proulx, Steven; Brown, Steven A.; Detmar, Michael; Kohler, Malcolm; Zenobi, Renato (2015-06-26). "Drug Pharmacokinetics Determined by Real-Time Analysis of Mouse Breath". Angewandte Chemie International Edition. 54 (27): 7815–7818. doi:10.1002/anie.201503312. hdl: 20.500.11850/102558 . PMID   26015026.
20. Sheiner LB, Rosenberg B, Marathe VV (October 1977). "Estimation of population characteristics of pharmacokinetic parameters from routine clinical data". Journal of Pharmacokinetics and Biopharmaceutics. 5 (5): 445–79. doi:10.1007/BF01061728. PMID   925881. S2CID   28622472.
21. Sheiner LB, Beal S, Rosenberg B, Marathe VV (September 1979). "Forecasting individual pharmacokinetics". Clinical Pharmacology and Therapeutics. 26 (3): 294–305. doi:10.1002/cpt1979263294. PMID   466923. S2CID   41194071.
22. Bonate PL (October 2005). "Recommended reading in population pharmacokinetic pharmacodynamics". The AAPS Journal. 7 (2): E363–73. doi:10.1208/aapsj070237. PMC   2750974 . PMID   16353916.
23. O'Valle, F.; García del Moral, R.; Andujar, M. (1995). "Mecanismos de nefrotoxicidad por ciclosporina A a nivel celular". Nefrologia (in Spanish). 15 Supplement 1. Archived from the original on 2018-07-26. Retrieved 2018-07-26.
24. Joaquín Herrera Carranza Manual de farmacia clínica y Atención Farmacéutica (in Spanish). Published by Elsevier España, 2003; page 159. ISBN   84-8174-658-4
25. Jager T, Albert C, Preuss TG, Ashauer R (April 2011). "General unified threshold model of survival--a toxicokinetic-toxicodynamic framework for ecotoxicology". Environmental Science & Technology. 45 (7): 2529–40. Bibcode:2011EnST...45.2529J. doi:10.1021/es103092a. PMID   21366215.
26. Ashauer R. "Toxicokinetic-Toxicodynamic Models – Ecotoxicology and Models". Swiss Federal Institute of Aquatic Science and Technology. Archived from the original on 2012-04-05. Retrieved 2011-12-03.
27. US EPA, OMS (2016-11-17). "Chemicals and Toxics Topics". www.epa.gov. Archived from the original on 2023-09-22. Retrieved 2022-05-15.
28. "Chemical safety". www.who.int. Archived from the original on 2024-01-21. Retrieved 2022-05-15.

External links

Software

Noncompartmental

• Freeware: bear and PK for R, MetidaNCA for Julia
• Commercial: PumasCP, MLAB, EquivTest, Kinetica, MATLAB/SimBiology, PKMP,Phoenix/WinNonlin, PK Solutions, RapidNCA.

Compartment based

• Freeware: ADAPT, Boomer (GUI), SBPKPD.org (Systems Biology Driven Pharmacokinetics and Pharmacodynamics), WinSAAM, PKfit for R, PharmaCalc and PharmaCalcCL, Java applications.
• Commercial: Pumas, PrecisePK, Imalytics, Kinetica, MATLAB/SimBiology, Phoenix/WinNonlin, PK Solutions, PottersWheel, ProcessDB, SAAM II.

Physiologically based

• Freeware: MCSim
• Commercial: Pumas, acslX, Cloe PK, GastroPlus, MATLAB/SimBiology, PK-Sim, ProcessDB, Simcyp, Entelos PhysioLab Phoenix/WinNonlin, ADME Workbench.

Population PK

• Freeware: WinBUGS, ADAPT, S-ADAPT / SADAPT-TRAN, Boomer, PKBugs, Pmetrics for R.
• Commercial: Pumas, PrecisePK, Kinetica, MATLAB/SimBiology, Monolix, NONMEM, Phoenix/NLME, PopKinetics for SAAM II, USC*PACK, DoseMe-Rx, Navigator Workbench.

Therapeutic drug monitoring (TDM)

• Commercial: Lyv, PrecisePK

Simulation

All model based software above.

• Freeware: Pumas, COPASI, Berkeley Madonna, MEGen.

Educational centres

Global centres with the highest profiles for providing in-depth training include the Universities of Buffalo, Florida, Gothenburg, Leiden, Otago, San Francisco, Beijing, Tokyo, Uppsala, Washington, Manchester, Monash University, and University of Sheffield. ^[1]

1. Tucker GT (June 2012). "Research priorities in pharmacokinetics". British Journal of Clinical Pharmacology. 73 (6): 924–6. doi:10.1111/j.1365-2125.2012.04238.x. PMC   3391520 . PMID   22360418.